Life Sciences

WIPO report: US patent filings dip for first time since 2009

The number of grants also drops while UK sees worrying fall in applications; but study has good news for EPO President Campinos

WIPO report: US patent filings dip for first time since 2009
15 Oct 2019

California’s first-of-a-kind reverse payment law is a further obstacle to litigation settlements

Pharma patent litigation settlements involving the transfer of “anything of value” to the generic are now presumed anti-competitive under Golden State law

14 Oct 2019

India's patent office appeal board paralysed again

Delhi court refuses to extend chairman’s tenure, leaving the body with just one expert on staff and a growing backlog

Latest

View all
11 Oct 2019

Data reveals strong growth in the number of female inventors, but there is still a long way to go

A report by the UK IP Office finds more women named on patents than ever before – but also that they remain woefully under-represented. We present the top takeaways from a very timely study Read more

8 Oct 2019

An eyebrow-raising CJEU ruling could be bad news for generics

Europe’s highest court has handed down a surprising decision concerning the consequences of an “unjustified” preliminary injunction issued in a pharma patent case Read more

4 Oct 2019

How AstraZeneca found success in out-licensing, in-licensing and a revamped R&D strategy

A steep patent cliff in 2012 forced the Anglo-Swedish company to rethink its entire operation – and the results have shown the right calls were made Read more

1 Oct 2019

Federal Circuit set to hear key patent eligibility case with far reaching consequences for hybrid technologies

Dispute between 23andMe and Ancestry.com will give rights owners insight into how court applies section 101 case law to rapidly growing area of digital health  Read more

News

View all
1 Oct 2019

The top biopharma patent stories in September

Our round-up of all the major IP developments affecting the life sciences industries last month Read more

12 Sep 2019

The Boston Manifesto - why IP needs more women and how to make it happen 

The IP world, particularly in the field of patents, continues to be dominated by men. A group of senior professionals from all parts of the IP ecosystem came together before this year's IPBC in Boston to discuss ways to encourage greater diversity and to produce recommendations to achieve it   Read more

11 Sep 2019

Five things to watch for from Japan’s new IP policy leadership

The new commissioner of the JPO and top cabinet advisor on IP will both address IPBC Asia in Tokyo in some of their first appearances in front of a global audience Read more

7 Sep 2019

Life sciences IP - the major developments in August

All the big pharma and biotech patent stories from last month in our regular monthly round-up Read more

Analysis

View all
30 Sep 2019

ITRI spin-out is plaintiff in latest genomics patent campaign

Taiwan’s Personal Genomics is going after an acquisition target of Illumina, the top player in the sequencing space Read more

26 Sep 2019

Allegations of sham pharma patent litigation are growing, but claimants have a mountain to climb

Akorn Inc’s failure to make its case against Allergan and Duke is a reminder that challenging life sciences patentees remains a tough task Read more

25 Sep 2019

South Korean president uses 2 millionth patent grant to call for tech independence

Moon Jae-in (centre) made the comments amid an international dispute with Japan. He also said IP can help prevent conglomerates from seizing technology from smaller firms Read more

24 Sep 2019

Latest CJEU developments will disappoint those seeking SPC clarity

Europe’s highest court has refused to tackle a long-standing question relating to third-party marketing approval, while its Advocate General has provided confusing guidance on Article 3(a) Read more

Insights

View all
24 May 2019

IP market news highlights

Some of the major news stories carried on the IAM platform from March to mid-May. Read more

1 Apr 2019

IP market news highlights

The big stories from the IAM platform in February and March. Read more